Tobacco is the world's leading preventable cause of disease and death. People with depression are twice as likely to smoke and are less responsive to standard tobacco treatments as compared to the general population. A Cochrane systematic review (Van der Meer 2013) of randomised controlled trials of smoking cessation treatment for smokers with current or historical depression found that adding psychosocial mood management to usual smoking treatment improved quit rates. However, the review did not examine if variation in intervention delivery or intervention functions impacted on treatment effectiveness.
STRENGTHS AND LIMITATIONS OF THIS STUDY
• We will examine the impact of variation in intervention delivery and functions on treatment effectiveness using peer-reviewed checklists: The Behaviour Change Taxonomy , and Template for Intervention Description and Replication (TIDieR, ).
• If analyses are possible, this study will provide causal effects of smoking treatment on depression symptoms in people with depression.
• May suffer from low power.
• May suffer from publication bias. 
BACKGROUND
Tobacco is the world's leading preventable cause of disease and death. 1 In the UK and in other developed nations smoking prevalence has declined substantially in the general population, but has remained largely unchanged in those with mental health problems resulting in an excess burden of smoking-related mortality in this group. 2, 3 People with depression are twice as likely to smoke 4, 5 and are less responsive to standard tobacco treatments than are the general population 6, 7 leading to urgent calls for targeted smoking interventions. 8 The Cochrane Group conducted a systematic review and meta-analysis of smoking cessation interventions for smokers with past or present depression. The review included pharmacological and behavioural interventions to aid cessation and found that adding psychosocial mood management to a usual smoking treatment (e.g., nicotine replacement therapy, telephone counselling, self-help website) moderately increased smoking cessation rates in people with current depression compared to usual smoking treatment alone, reporting a risk ratio of 1.47 (95% confidence interval: 1.13 to 1.92). 9 The review highlighted the importance of adding psychosocial techniques to handle depressive symptoms in standard smoking treatments for people with depression. However, in the meta-analysis there was variation between the included studies' direction of effect and it is possible that this variation may be in part related to differences in intervention delivery, intervention functions, or tailoring, for example. Further investigation into these potential modifiers will provide useful information for development of smoking cessation interventions for people with current depression. 9 In addition, the review did not examine the impact of behavioural or psychological smoking cessation interventions on depression symptoms. This is an important question as many clinicians believe that smoking may offer mental health benefits, or that their patients' mental health may deteriorate upon cessation. 10 However, there are data from meta-analyses of cohort studies indicating that quitting smoking may improve depression, 11 but due to common pitfalls of observational cohort studies one cannot be sure that this is a causal association. If treating smoking is found to not worsen depression, then these data can be used to assure clinicians that they are not causing psychological harm by helping their patients to quit smoking.
In our review, we aim to add-on to the previous Cochrane review in three ways. We will:
1) Use the Template for Intervention Description and Replication checklist (TIDieR) 12 to determine if variations in delivery of mood management components impact on intervention effectiveness. 2) Use the Taxonomy of Behaviour Change techniques for smoking cessation 13 to examine which behaviour change functions are most effective for smoking cessation in people with current depression. 3) Examine the difference in change in depression scores between intervention and control arms. 
METHODS
The study protocol will be registered in advance on the International Prospective Register of Systematic Reviews (PROSPERO; http://www.crd.york.ac.uk/PROSPERO/), uploaded to bioRxiv (http://biorxiv.org/), and submitted for publication to a peer-reviewed journal. All methods and study reporting will adhere to guidance described within the Cochrane Handbook for Systematic Reviews and Meta-analyses of Randomised Controlled Trials.
14

Inclusion criteria
• Study design: Randomised controlled trials only;
• Participants: Daily smokers with current depression, any definition of depression, no restrictions by physical or mental comorbidities;
• Intervention: Any smoking cessation intervention;
• Intervention delivery: Self-help, individual, group, internet;
• Control: Any (e.g., including self-help, no treatment, etc.);
• Outcome: Any ascertainment of smoking cessation;
• Follow-up: Follow up at a minimum of 6-months from the quit date.
Outcomes:
• Smoking status at final follow-up;
• Change in depression scores from baseline to final follow-up.
Search strategy
We will include relevant studies identified by a previously conducted Cochrane review of smoking cessation interventions for people with depression. 9 This review will be updated this year and we will also include relevant studies from the updated version of the review.
Data extraction
We will extract the following data from included trials:
Trial methods: Study design, setting, country, randomisation methods.
Participants:
Number of participants per intervention group, definition of depression, type of smoker, comorbid conditions, age, sex, ethnicity, level of education, nicotine dependence, mean/median number of cigarettes per day (CPD), depression type and severity.
Interventions: Description of the interventions, the number of and function of behaviour change techniques used (where sufficient details are not reported in text, we will attempt to obtain intervention protocols), presence or absence of TIDieR checklist items. Description of the control, the number of and function of behaviour change techniques used (where sufficient details are not reported in text, we will attempt to obtain intervention protocols), presence or absence of TIDieR checklist items.
Outcomes:
Smoking cessation status, biochemical validation, depression scores, length of follow-up.
Coding of Template for Intervention Description and Replication checklist (TIDieR)
For study aim 1 we will use the Template for Intervention Description and Replication checklist (TIDieR) 12 to determine if variations in delivery of mood management components impact on intervention effectiveness. We will use a modified version of the template as not all questions on the checklist are useful in the context of this study (e.g. "Describe any rationale, theory, or goal of the elements essential to the intervention"). Coding will be conducted separately by two researchers to confirm agreement.
Coding of behaviour change intervention functions:
We will categorise behaviour change techniques according to their function and record whether the function was either absent or present during intervention delivery 13 (Table 2 ). Coding will be conducted separately by two researchers to confirm agreement.
Measures of treatment effect Smoking cessation (Study aims 1 & 2):
We will present treatment effects as risk ratios (RR) and 95% confidence intervals 14 . RRs will be calculated as follows: (number of participants who quit smoking in the intervention group/number of participants randomised to intervention group) divided by (number of participants who quit smoking in control group/number of participants randomised to the control group).
Difference in change in depression scores between trial arms (Study aim 3): We will present the standardised mean difference (SMD), and 95% confidence intervals of change in depression scores between treatment arms, from baseline to follow-up.
Analysis
All analyses will be conducted using Stata 14.
Study aim 1 -Do variations in delivery of mood management components impact on intervention effectiveness: If there are sufficient data, we will conduct random effects meta-regression using the metareg command 15 in which modified TIDieR Checklist items (see Table 1 ) will be regressed on the study's effect estimate. First, univariate analyses will be conducted to determine the association between each item and the study effect size. Subsequently, items with the strongest association will be added to the meta-regression model first, and all other variables will be added in turn regardless of significance in the univariate model. If there are sufficient data, we will conduct random effects meta-regression using the metareg command 15 in which behaviour change functions (see Table 2 ) will be regressed on the study's effect estimate. First, univariate analyses will be conducted to determine the association between each intervention component and the study effect size. Subsequently, variables with the strongest association will be added to the meta-regression model first, and all other variables will be added in turn regardless of significance in the univariate model.
Study aim 3 -Examine the difference in change in depression scores between intervention and control arms: If there are sufficient data, we will use a generic inverse variance random effects model to pool the standardised mean difference (SMD) of change in depression scores in treatment and control arms, from baseline to follow-up. We will use a random effects model as it incorporates heterogeneity both within and between studies.
Statistical heterogeneity:
We will quantify statistical heterogeneity using I 2 which describes the percentage (%) of betweenstudy variability due to heterogeneity rather than chance; values over 50% suggest substantial heterogeneity, and values over 75% suggest considerable heterogeneity. 14 Tau 2 will be used to test whether differences between studies' effect estimates are compatible with chance alone. 16 Sensitivity and subgroup analyses: We will conduct sensitivity analyses to examine if the following study characteristics influence the meta-analysis results: study quality (as measured by Cochrane's Risk of Bias tool), loss-to-follow-up, and severity of depression.
Assessment of publication bias:
We will examine funnel plots for evidence of asymmetry and conduct egger tests for evidence of small study bias using the metabias command. 
ETHICAL APPROVAL
Ethical approval is not required for this study.
DISSEMINATION
We will disseminate the findings of this work at international and national conferences, and to the UK Centre for Tobacco and Alcohol Studies Smokers' Panel.
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COMPETING INTERESTS
STRENGTHS AND LIMITATIONS OF THIS STUDY 68
• We will examine the impact of variation in intervention delivery and functions on treatment 69 effectiveness using peer-reviewed checklists: The Behaviour Change Taxonomy (Michie et al,  70 2011), and Template for Intervention Description and Replication (TIDieR, Hoffmann et al, 71 2014). 72
• If analyses are possible, this study will provide causal effects of smoking treatment on 73 depression symptoms in people with depression. 74
• May suffer from low power. 75
• May suffer from publication bias. 76
Not all intervention details may be reported. We will request intervention manuals from study 77 authors, however these may not always be possible to obtain. 78 The Cochrane Group conducted a systematic review and meta-analysis of smoking cessation 88 interventions for smokers with past or present depression. The review included pharmacological and 89 behavioural interventions to aid cessation and found that adding psychosocial mood management to 90 a usual smoking treatment (e.g., nicotine replacement therapy, telephone counselling, self-help 91 website) moderately increased smoking cessation rates in people with current depression compared 92 to usual smoking treatment alone, reporting a risk ratio of 1.47 (95% confidence interval: 1.13 to 93
1.92). 9 The review highlighted the importance of adding psychosocial techniques to handle 94 depressive symptoms in standard smoking treatments for people with depression. However, in the 95 meta-analysis there was variation between the included studies' direction of effect and it is possible 96 that this variation may be in part related to differences in intervention delivery, intervention 97 functions, or tailoring, for example. Further investigation into these potential modifiers will provide 98 useful information for development of smoking cessation interventions for people with current 99 depression.
9 100 101 In addition, the review did not examine the impact of behavioural or psychological smoking 102 cessation interventions on depression symptoms. This is an important question as many clinicians 103 believe that smoking may offer mental health benefits, or that their patients' mental health may 104 deteriorate upon cessation. 10 However, there are data from meta-analyses of cohort studies 105 indicating that quitting smoking may improve depression, 11 but due to common pitfalls of 106 observational cohort studies one cannot be sure that this is a causal association. If treating smoking 107 is found to not worsen depression, then these data can be used to assure clinicians that they are not 108 causing psychological harm by helping their patients to quit smoking. 109 110
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Analysis
207
We will conduct analyses using Stata 14 or Revman software. 208
The following analytical procedures for each study aim are as follows: 209
1. Do variations in delivery of mood management components impact on intervention 210 effectiveness: If there are sufficient data, we will conduct random effects meta-regression using 211 the metareg command 15 in which modified TIDieR Checklist items (see Table 1 ) will be 212 regressed on the study's effect estimate. First, univariate analyses will be conducted to 213 determine the association between each item and the study effect size. Subsequently, items 214 with the strongest association will be added to the meta-regression model first, and all other 215 variables will be added in turn regardless of significance in the univariate model. 216
2. Use the Taxonomy of Behaviour Change techniques for smoking cessation to examine which 217 behaviour change functions are most effective for smoking cessation in people with current 218 depression: If there are sufficient data, we will conduct random effects meta-regression using 219 the metareg command 15 in which behaviour change functions (see Table 2 ) will be regressed 220 on the study's effect estimate. First, univariate analyses will be conducted to determine the 221 association between each intervention component and the study effect size. Subsequently, 222
variables with the strongest association will be added to the meta-regression model first, and all 223 other variables will be added in turn regardless of significance in the univariate model. 224
3. Examine the difference in change in depression scores between intervention and control 225 arms: If there are sufficient data, we will use a generic inverse variance random effects model to 226 pool the standardised mean difference (SMD) of change in depression scores in treatment and 227 control arms, from baseline to follow-up. We will use a random effects model as it incorporates 228 heterogeneity both within and between studies. 229 Statistical heterogeneity: We will quantify statistical heterogeneity using I 2 which describes the 230 percentage (%) of between-study variability due to heterogeneity rather than chance; values over 231 50% suggest substantial heterogeneity, and values over 75% suggest considerable heterogeneity. 14 232 Tau 2 will be used to test whether differences between studies' effect estimates are compatible with 233 chance alone. 16 
234
Sensitivity and subgroup analyses: We will conduct sensitivity analyses to examine if the following 235 study characteristics influence the meta-analysis results: study quality (as measured by Cochrane's 236
Risk of Bias tool), loss-to-follow-up, and severity of depression. 237
Assessment of publication bias: We will examine funnel plots for evidence of asymmetry and 238 conduct egger tests for evidence of small study bias using the metabias command. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r p e e r r e v i e w o n l y 
PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols
METHODS
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
5-6
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 5 Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated n/a 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 6
Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) n/a Data collection process 11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators 6 Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications
6
Outcomes and prioritization 13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale 5-6
Risk of bias in individual studies
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis 7
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 6-7 15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I 2 , Kendall's τ)
6-7
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 7 15d If quantitative synthesis is not appropriate, describe the type of summary planned 6-7 Meta-bias(es)
16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 6-7 Confidence in cumulative evidence 17 Describe how the strength of the body of evidence will be assessed (such as GRADE) n/a * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 With the aim of providing information to develop tailored approaches to treating smoking for people 47 with current depression we will add-on to the Cochrane review in three ways: 1) Use the Template 48
for Intervention Description and Replication checklist to determine if variations in mood 49 management delivery impact on intervention effectiveness, 2) Use the Taxonomy of Behaviour 50
Change Techniques for smoking cessation to examine which behaviour change functions are most 51 effective for smoking cessation in people with current depression, 3) Examine the difference in 52 change in depression scores between intervention and control arms. 53 54
Methods and Analysis 55
We will include randomised controlled trials of smokers with current depression as identified by the 56 previous Cochrane review and the in-progress update of the Cochrane review. We will use meta-57 regression to examine 1) if variations in delivery of mood management impact on smoking cessation 58 intervention effectiveness, 2) determine which behaviour change functions are most effective for 59 smoking cessation and 3) use meta-analysis of the difference in change in depression scores 60 between treatment arms from baseline to follow-up to determine if offering smoking cessation 61 treatment causes psychological harm. 62 63 64
Ethics and Dissemination 65 Ethical approval is not required for this study. We will disseminate the findings of this work at 66 conferences, and to relevant patient panels. 67 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Registration details
60 F o r p e e r r e v i e w o n l y 3
STRENGTHS AND LIMITATIONS OF THIS STUDY 70
• We will examine the impact of variation in intervention delivery and intervention functions 71 on treatment effectiveness using peer-reviewed checklists: The Behaviour Change 72 Taxonomy, and Template for Intervention Description and Replication. 73
• The study design may suffer from low power and/or publication bias. 74
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The Cochrane Group conducted a systematic review and meta-analysis of smoking cessation 84 interventions for smokers with past or present depression. The review included pharmacological and 85 behavioural interventions to aid cessation and found that adding mood management to a usual 86 smoking treatment (e.g., nicotine replacement therapy, telephone counselling, self-help website) 87 moderately increased smoking cessation rates in people with current depression compared to usual 88 smoking treatment alone, reporting a risk ratio of 1.47 (95% confidence interval: 1.13 to 1.92). 9 The 89 review highlighted the importance of adding psychological techniques to handle depressive 90 symptoms in standard smoking treatments for people with depression. However, in the meta-91 analysis there was variation between the included studies' direction of effect and it is possible that 92 this variation may be in part related to differences in intervention delivery or intervention functions, 93 for example. Further investigation into these potential modifiers will provide useful information for 94 development of smoking cessation interventions for people with current depression. In addition, the review did not examine the impact of behavioural or psychological smoking 97 cessation interventions on depression symptoms. This is an important question as many clinicians 98 believe that smoking may offer mental health benefits, or that their patients' mental health may 99 deteriorate upon cessation. 10 However, there are data from meta-analyses of cohort studies 100 indicating that quitting smoking may improve depression, 11 but due to common pitfalls of 101 observational data one cannot be sure that this is a causal association. If treating smoking is found to 102 not worsen depression, then these data can be used to assure clinicians that they are not causing 103 psychological harm by helping their patients to quit smoking. 104 105
In our review, we aim to add-on to the 2013 Cochrane review 9 in three ways. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 We will extract the following additional data not reported by in the 2013 Cochrane review 9 : 162
• Interventions -The number of and function of behaviour change techniques used (i.e. where 163 sufficient details are not reported in text, we will attempt to obtain intervention protocols), 164 and presence or absence of TIDieR checklist items. 165
• Control -The number of and function of behaviour change techniques used (i.e. where 166 sufficient details are not reported in text, we will attempt to obtain intervention protocols), 167
and presence or absence of TIDieR checklist items. 168
• Measures of treatment effect, depression symptoms (Study aim 3): For each trial arm, we 169 will obtain mean depression scores and measure of variance at baseline and follow-up, 170 mean differences and measures of variance from baseline to follow-up, or differences in 171 change between trial arms' scores from baseline to follow-up and measures of variance. 172
Coding of Template for Intervention Description and Replication checklist (TIDieR) 173
The 2013 Cochrane review 9 did not extract any information relevant to the TIDieR checklist 12 , these 174 data are new to this review. 175 176
For study aim 1 we will use the TIDieR checklist 12 to determine if variations in mood management 177 delivery impact on intervention effectiveness. We will use a modified version of TIDieR as not all 178 items on the checklist are useful in the context of this study ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 sufficient data, we will conduct random effects meta-regression models using the metareg 205 command 15 in which modified TIDieR checklist items (see Table 1 ) will be regressed on the 206 study's effect estimate. First, univariate analyses will be conducted to determine the association 207 between each item and the study effect size. Subsequently, items with the strongest association 208 will be added to the meta-regression model first, and all other variables will be added in turn 209 regardless of significance in the univariate model. 210
2. Use the Taxonomy of Behaviour Change techniques for smoking cessation to examine which 211 behaviour change functions are most effective for smoking cessation in people with current 212 depression: If there are sufficient data, we will conduct random effects meta-regression models 213 using the metareg command 15 in which behaviour change functions (see Table 2 ) will be 214 regressed on the study's effect estimate. First, univariate analyses will be conducted to 215 determine the association between each intervention function and the study effect size. 216
Subsequently, variables with the strongest association will be added to the meta-regression 217 model first, and all other variables will be added in turn regardless of significance in the 218 univariate model. 219 3. Examine the difference in change in depression scores between intervention and control 220 arms: If there are sufficient data, we will use a generic inverse variance random effects model to 221 pool the standardised mean difference (SMD) of change in depression scores in treatment and 222 control arms, from baseline to follow-up. We will use a random effects model as it incorporates 223 heterogeneity both within and between studies. 224 Statistical heterogeneity: We will quantify statistical heterogeneity using I 2 which describes the 225 percentage (%) of between-study variability due to heterogeneity rather than chance; values over 226 50% suggest substantial heterogeneity, and values over 75% suggest considerable heterogeneity. 14 227 Tau 2 will be used to test whether differences between studies' effect estimates are compatible with 228 chance alone. 16 
229
Sensitivity and subgroup analyses: We will conduct sensitivity analyses to examine if the following 230 study characteristics influence the meta-analysis results: study quality (as measured by Cochrane's 231
Risk of Bias tool), loss-to-follow-up, and severity of depression. 232
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METHODS
5-6
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage 5 Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated n/a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48 
